Glucagon-like peptide-1 receptor agonists as add-on therapy to basal insulin in patients with type 2 diabetes: a systematic review

References

• Flegal KM Carroll MD Ogden CL Curtin LR Prevalence and trends in obesity among US adults, 1999–2008 JAMA 2010 303 235 241 20071471
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention National Diabetes Fact Sheet 2011 Atlanta US Department of Health and Human Services, Centers for Disease Control and Prevention 2011
   Google Scholar
• Arbeeny CM Addressing the unmet medical need for safe and effective weight loss therapies Obes Res 2004 12 1191 1196 15340099
   PubMedGoogle Scholar
• UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 1998 352 837 853 9742976
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) Lancet 1998 352 854 865 9742977
   PubMed Web of Science ®Google Scholar
• Inzucchi SE Bergenstal RM Buse JB Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care Epub April 19, 2012
   Web of Science ®Google Scholar
• Nauck MA Wollschlager D Werner J Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7–36 amide]) in patients with NIDDM Diabetologia 1996 39 1546 1553 8960841
   PubMed Web of Science ®Google Scholar
• Larsson H Holst JJ Ahren B Glucagon-like peptide-1 reduces hepatic glucose production indirectly through insulin and glucagon in humans Acta Physiol Scand 1997 160 413 422 9338524
   PubMedGoogle Scholar
• Flint A Raben A Astrup A Holst JJ Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans J Clin Invest 1998 101 515 520 9449682
   PubMed Web of Science ®Google Scholar
• Drucker DJ Glucagon-like peptides Diabetes 1998 47 159 169 9519708
   PubMed Web of Science ®Google Scholar
• Bagger JI Knop FK Lund A Vestergaard H Holst JJ Vilsboll T Impaired regulation of the incretin effect in patients with type 2 diabetes J Clin Endocrinol Metab 2011 96 737 745 21252240
   PubMed Web of Science ®Google Scholar
• Shyangdan DS Royle P Clar C Sharma P Waugh N Snaith A Glucagon-like peptide analogues for type 2 diabetes mellitus Cochrane Database Syst Rev 2011 10 CD006423 21975753
   PubMed Web of Science ®Google Scholar
• Byetta (exenatide) [package insert] San Diego Amylin Pharmaceuticals 2009
   Google Scholar
• Pinelli NR Hurren KM Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis Ann Pharmacother 2011 45 850 860 21730278
   PubMed Web of Science ®Google Scholar
• Victoza (liraglutide) [package insert] Princeton Novo Nordisk 2010
   Google Scholar
• Moher D Liberati A Tetzlaff J Altman DG Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement Ann Intern Med 2009 151 264 269 19622511
   PubMed Web of Science ®Google Scholar
• Buse JB Bergenstal RM Glass LC Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial Ann Intern Med 2011 154 103 112 21138825
   PubMed Web of Science ®Google Scholar
• Riddle MC Rosenstock J Gerich J The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients Diabetes Care 2003 26 3080 3086 14578243
   PubMed Web of Science ®Google Scholar
• Arnolds S Dellweg S Clair J Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study Diabetes Care 2010 33 1509 1515 20357372
   PubMed Web of Science ®Google Scholar
• Riddle M Ahmann A Basu A Aroda V Ratner R Metformin+ exenatide+basal insulin vs metformin+placebo+basal insulin: reaching A1c < 6.5% without weight-gain or serious hypoglycemia Diabetes 2010 59 Suppl 1 Abstract 18-LB
   Google Scholar
• Morrow L Hompesch M Guthrie H Chang D Chatterjee DJ Co-administration of liraglutide with insulin detemir demonstrates additive pharmacodynamic effects with no pharmacokinetic interaction Diabetes Obes Metab 2011 13 75 80 21114606
   PubMed Web of Science ®Google Scholar
• Seino Y Min K Niemoller E Takami A Lixisenatide significantly improves glycemic control in Asian patients with T2DM insufficiently controlled on basal insulin +/– SU Diabetes 2011 60 Suppl 1 Abstract 278-OR
   Google Scholar
• Holman RR Thorne KI Farmer AJ Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes N Engl J Med 2007 357 1716 1730 17890232
   PubMed Web of Science ®Google Scholar
• Rosenstock J Davies M Home PD Larsen J Koenen C Schernthaner G A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes Diabetologia 2008 51 408 416 18204830
   PubMed Web of Science ®Google Scholar
• Apidra (insulin glulisine [rDNA origin] injection) [package insert] Bridgewater Sanofi-Aventis US 2009
   Google Scholar
• Humalog (insuln lispro injection) [package insert] Indianapolis Lilly USA 2011
   Google Scholar
• Novolog (insulin aspart [rDNA origin] injection) [package insert] Princeton Novo Nordisk 2009
   Google Scholar
• Vilsboll T Rosenstock J Yki-Jarvinen H Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes Diabetes Obes Metab 2010 12 167 177 20092585
   PubMed Web of Science ®Google Scholar
• Mendoza CA Mathew M Chen J Exenatide promotes weight loss and improves insulin secretion, subclinical inflammation and hepatic steatosis when replaced for pre-meal insulin in T2DM patients Diabetes 2009 58 Supp 1 Abstract 507
   Google Scholar
• Davidson MH Cardiovascular effects of glucagonlike peptide-1 agonists Am J Cardiol 2011 108 33B 41B
   Web of Science ®Google Scholar
• Drucker DJ The biology of incretin hormones Cell Metab 2006 3 153 165 16517403
   PubMed Web of Science ®Google Scholar